Skip to main content
PAINWeek 2025 Main banner
Icon Legend
This session is not in your agenda.
This session is in your agenda. Click to remove it

Biologic Innovation in Pain Management: Monoclonal Antibodies Targeting IL-6, TNF-α, TRPV1, and Neuroinflammatory Pathways

P-035 - (Poster #35) Biologic Innovation in Pain Management: Monoclonal Antibodies Targeting IL-6, TNF-α, TRPV1, and Neuroinflammatory Pathways

Thursday, September 4, 2025
4:00 PM - 5:30 PM PST
Location:  Exhibit Hall (Level 4)
Background: Chronic pain, particularly neuropathic pain, represents a substantial clinical and societal burden. It affects millions worldwide, significantly impairing quality of life and daily functioning. Despite advancements in pharmacologic and interventional therapies, chronic pain remains difficult to treat, with a high prevalence of partial or non-responders and adverse effects from traditional medications, including opioids. Recent interest has shifted toward biologic therapies, particularly monoclonal antibodies (mAbs), that modulate pain-related inflammatory and sensory pathways. While nerve growth factor (NGF) inhibition has dominated prior research, focus is now expanding to alternative targets such as cytokines and ion channels, offering potentially safer and more effective strategies for long-term pain management.

Purpose/Objectives: This structured literature review aims to examine the therapeutic potential of monoclonal antibodies targeting emerging mediators of chronic pain beyond NGF. Specifically, the review evaluates evidence on monoclonal antibodies targeting IL-6, TNF-α, TRPV1, and other biologics that address neuroinflammation, central sensitization, and nociceptor activation in neuropathic and inflammatory pain conditions.

Methods: A comprehensive literature review was conducted using PubMed. The following advanced PubMed search string was utilized for data extraction: ("biased opioid agonists" AND "chronic pain" AND "analgesia") OR ("monoclonal antibodies" AND "NGF" AND "pain") OR ("TRPV1" AND "chronic pain treatment") OR ("bradykinin" AND "pain management" AND "novel therapies"). Studies published within the past 10 years were included, with a focus on clinical trials and systematic reviews. Primary outcomes assessed the efficacy of biased opioid agonists and mAbs in reducing pain and minimizing side effects, while secondary outcomes included safety profiles, drug interactions, and patient outcomes in chronic pain conditions.

Results: Monoclonal antibodies targeting IL-6 and TNF-α demonstrated significant pain reduction and improved function in inflammatory and neuropathic conditions such as rheumatoid arthritis and sciatica. These therapies were generally well tolerated and had a more favorable safety profile than NSAIDs and opioids. Preclinical studies of anti-TRPV1 antibodies showed decreased nociceptor activation and thermal hyperalgesia, suggesting translational potential. Additional targets, including fractalkine (CX3CL1) and purinergic P2X3 receptors, showed reduced neuroinflammation and central sensitization in models of post-surgical and chemotherapy-induced pain. Biased opioid agonists such as PZM21 provided strong analgesia in animal models with fewer side effects, including reduced respiratory depression and addictive potential. However, clinical data remain limited. Similarly, anti-NGF monoclonal antibodies like tanezumab improved osteoarthritis symptoms in non-responders to conventional therapy but have been associated with joint-related adverse events, limiting use. Emerging therapies targeting bradykinin and TRPV1 receptors are undergoing early-phase trials. Preliminary findings suggest effective pain relief with fewer opioid-like side effects, though long-term safety and cost remain concerns. Overall, these novel therapies offer promising alternatives to traditional pain management, with early evidence of efficacy and improved tolerability. Continued research is needed to validate these findings in diverse patient populations.

Conclusions/Implications for future research and/or clinical care: Biased opioid agonists and monoclonal antibodies targeting non-NGF pathways represent a promising shift in pain management. These therapies offer effective analgesia with fewer opioid-related side effects, such as respiratory depression and addiction. Agents targeting IL-6, TNF-α, TRPV1, and other neuroinflammatory mediators show early clinical and preclinical efficacy in chronic and neuropathic pain conditions. However, challenges remain, including high costs, potential immunogenicity, and the need for precise patient selection. Further large-scale trials are needed to assess long-term safety, effectiveness, and cost-benefit profiles. Identifying specific pain phenotypes and treatment predictors will be key for clinical integration. With continued research, these innovative therapies may offer safer, more personalized alternatives to traditional opioids and reshape the future of chronic pain care.